Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Differentiated Thyroid Cancer × vandetanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 24 Lung Neoplasms 14 Carcinoma, Medullary 14 Neoplasm Metastasis 12 Neoplasms 10 Thyroid Neoplasms 8 Breast Neoplasms 8 Glioma 6 Prostatic Neoplasms 5 Glioblastoma 5 Squamous Cell Carcinoma of Head and Neck 4 Gliosarcoma 4 Colorectal Neoplasms 4 Brain Neoplasms 4 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Head and Neck Neoplasms 3 Carcinoma, Renal Cell 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Thyroid Cancer, Papillary 2 Stomach Neoplasms 2 Recurrence 2 Rectal Neoplasms 2 Pleural Effusion 2 Kidney Neoplasms 2 Familial medullary thyroid carcinoma 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2 Disease Progression 2

Interventions

Thyrotropin Alfa 4 donafenib 2 Injections 2 vandetanib 1 surufatinib 1 pembrolizumab 1 lenvatinib 1 apatinib 1 anlotinib 1 Sorafenib 1 Iodine-131 1 Everolimus 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01876784 2024-07-23

VERIFY

Sanofi

Phase 3 Completed

238 enrolled 12 charts

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡